{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:50:05Z","timestamp":1792176605453,"version":"4.4.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Macrolide antibiotics are largely used in pregnancy for different bacterial infections. Their fetal safety has been studied by several groups, yielding opposing results. In particular, there have been studies claiming an association between macrolides and cardiovascular malformations. Exposure in early infancy has been associated with pyloric stenosis and intussusception. This has led to an avoidance in prescribing macrolides to pregnant women in several Scandinavian countries. The Objectives of the present study was to investigate the fetal safety of this class of drug by linking a large administrative database of drug dispensing and pregnancy outcome in Southern Israel. A computerized database of medications dispensed from 1999 to 2009 to all women registered in the Clalit health maintenance organization in southern Israel was linked with two computerized databases containing maternal and infant hospitalization records. Also, medical pregnancy termination data were analyzed. The following confounders were controlled for: maternal age, ethnicity, maternal pregestational diabetes, parity, and the year the mother gave birth or went through medical pregnancy termination. First- and third-trimester exposures to macrolide antibiotics as a group and to individual drugs were analyzed. During the study period there were 105,492 pregnancies among Clalit women that met the inclusion criteria. Of these, 104,380 ended in live births or dead fetuses and 1,112 in abortion due to medical reasons. In the first trimester of pregnancy, 1,033 women were exposed to macrolides. There was no association between macrolides and either major malformations [odds ratio (OR), 1.08; 95% confidence interval (CI), 0.84 to 1.38)] or specific malformations, after accounting for maternal age, parity, ethnicity, prepregnancy diabetes, and year of exposure. During the third trimester of pregnancy, 959 women were exposed to macrolides. There was no association between such exposure and perinatal mortality, low birth weight, low Apgar score, or preterm delivery. Similarly, no associations were demonstrated with pyloric stenosis or intussusception. Use of macrolides in the first trimester of pregnancy is not associated with an increased risk of major malformations. Exposure in the third trimester is not likely to increase neonatal risks for pyloric stenosis or intussusception in a clinically meaningful manner.<\/jats:p>","DOI":"10.1128\/aac.01691-12","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T03:58:33Z","timestamp":1367899113000},"page":"3307-3311","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["Fetal Safety of Macrolides"],"prefix":"10.1128","volume":"57","author":[{"given":"Anat","family":"Bahat Dinur","sequence":"first","affiliation":[{"name":"Departments of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"},{"name":"BeMORE Collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure Collaboration), Beer-Sheva, Israel, and Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[{"name":"The Motherisk Program, Division of Clinical Pharmacology-Toxicology, Department of Pediatrics, Hospital for Sick Children, The University of Toronto, Toronto, Canada"},{"name":"BeMORE Collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure Collaboration), Beer-Sheva, Israel, and Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[{"name":"The Motherisk Program, Division of Clinical Pharmacology-Toxicology, Department of Pediatrics, Hospital for Sick Children, The University of Toronto, Toronto, Canada"},{"name":"BeMORE Collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure Collaboration), Beer-Sheva, Israel, and Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Wiznitzer","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"},{"name":"Soroka Medical Center, Beer-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Uziel","sequence":"additional","affiliation":[{"name":"Social Work Services, Beer-Sheva, Israel"},{"name":"Soroka Medical Center, Beer-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Gorodischer","sequence":"additional","affiliation":[{"name":"Pediatrics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"},{"name":"Soroka Medical Center, Beer-Sheva, Israel"},{"name":"Clalit Health Services (Southern District), Beer-Sheva, Israel"},{"name":"BeMORE Collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure Collaboration), Beer-Sheva, Israel, and Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Levy","sequence":"additional","affiliation":[{"name":"Departments of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel"},{"name":"BeMORE Collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure Collaboration), Beer-Sheva, Israel, and Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"799","volume-title":"Basic and clinical pharmacology","author":"Katzung BG","year":"2009","unstructured":"KatzungBG MastersSB TrevorAJ. 2009. Basic and clinical pharmacology, 11th ed. p 799\u2013801. McGraw-Hill, New York, NY.","edition":"11"},{"key":"e_1_3_1_3_2","first-page":"1521","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Chambers HF","year":"2011","unstructured":"ChambersHF. 2011. Protein synthesis inhibitors and miscellaneous antibacterial agents, p 1521\u20131547. In BruntonLL ChabnerBA KnollmannBC (ed). Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. McGraw Hill, New York, NY.","edition":"12"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383322"},{"key":"e_1_3_1_5_2","first-page":"61","article-title":"Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy","volume":"84","author":"Bush MR","year":"1994","unstructured":"BushMR RosaC. 1994. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet. Gynecol. 84:61\u201363.","journal-title":"Obstet. Gynecol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00586-3"},{"key":"e_1_3_1_7_2","first-page":"12","article-title":"Efficacy of Azithromycin in reducing lower genital ureaplasma urealyticum colonization in women at risk for preterm delivery","volume":"8","author":"Ogasawara K","year":"1999","unstructured":"OgasawaraK GoodwinM. 1999. Efficacy of Azithromycin in reducing lower genital ureaplasma urealyticum colonization in women at risk for preterm delivery. J. Matern. Fetal Med. 8:12\u201316.","journal-title":"J. Matern. Fetal Med"},{"key":"e_1_3_1_8_2","volume-title":"The Cochrane Collaboration","author":"Kenyon S","year":"2009","unstructured":"KenyonS BoulvainM NeilsonJP. 2009. Antibiotics for preterm rupture of membranes. The Cochrane Collaboration. John Wiley & Sons, Ltd., New York, NY."},{"key":"e_1_3_1_9_2","first-page":"419","article-title":"Comparison of azithromycin and erythromycin, for Chlamydia cervicitis in pregnancy","volume":"170","author":"Edwards M","year":"1994","unstructured":"EdwardsM RainwaterK CarterS. 1994. Comparison of azithromycin and erythromycin, for Chlamydia cervicitis in pregnancy. Am. J. Obstet. Gynecol. 170:419.","journal-title":"Am. J. Obstet. Gynecol"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2000.tb13339.x"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.141"},{"key":"e_1_3_1_12_2","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonate risk","author":"Briggs GG","year":"2011","unstructured":"BriggsGG FreemanRK YaffeSJ. 2011. Drugs in pregnancy and lactation: a reference guide to fetal and neonate risk, 9th ed. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"9"},{"key":"e_1_3_1_13_2","volume-title":"Birth defects and drugs in pregnancy","author":"Heinonen OP","year":"1977","unstructured":"HeinonenOP SloneD ShapiroS. 1977. Birth defects and drugs in pregnancy. Publishing Science Group, Littleton, MA."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04286.x"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(03)00012-1"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2008.07.008"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/11630920-000000000-00000"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-6-18"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/14767050500439657"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994053"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.538"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.7.647"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225130-00004"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp217"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010390806"},{"key":"e_1_3_1_26_2","unstructured":"The Israeli Central Bureau of Statistics (CBS). 2013. Statistical abstracts of Israel 2008. No. 59. Population by district subdistrict and religion. http:\/\/www.cbs.gov.il\/reader\/shnaton\/templ_shnaton_e.html?num_tab=st02_06x&CYear=2008. Accessed 7 April 2013."},{"key":"e_1_3_1_27_2","unstructured":"The Israeli Central Bureau of Statistics (CBS). 2013. Patterns of fertility in 2006. http:\/\/www.cbs.gov.il\/hodaot2007n\/01_07_215b.pdf. Accessed 7 April 2013."},{"key":"e_1_3_1_28_2","unstructured":"The Israeli Central Bureau of Statistics (CBS). 2013. Local authorities by socio-economic index value rank and cluster membership http:\/\/www.cbs.gov.il\/hodaot2013n\/24_13_087_local_autorities_a2.xls. Accessed 7 April 2013."},{"key":"e_1_3_1_29_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. 2012. ATC\/DDD index 2013. http:\/\/www.whocc.no\/atcddd\/. Accessed 15 February 2012."},{"key":"e_1_3_1_30_2","unstructured":"Centers for Disease Control and Prevention. 2011. Metropolitan Atlanta Congenital Defects Program. http:\/\/www.cdc.gov\/ncbddd\/bd\/macdp.htm. Accessed 6 June 2011."},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10111"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10012"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807154"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804163381607"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01691-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01691-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:34:20Z","timestamp":1645482860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01691-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/AAC.01691-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.01691-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"2012-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}